Uncontrolled #seizures can progress to more severe and complex types that require urgent, emergency care. Find out about Rapid and Early Seizure Termination (REST) and the new consensus recommendations published in EpiDisorders https://lnkd.in/eR5kbeRM
About us
UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With approximately 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2023 Key Financials: € 5.3 billion global revenue Specialties: Neurology, Immunology
- Website
-
http://www.ucb.com
External link for UCB
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Brussels
- Type
- Privately Held
- Founded
- 1928
- Specialties
- Neurology, Immunology, and Healthcare Innovation Beyond Medicine
Locations
Employees at UCB
Updates
-
Hear from Konrad J. Werhahn, Head of Global Medical Affairs, Epilepsy & Rare Syndromes discuss how we’re exploring disease modification in #epilepsy research. Read more in Pharmafile.com https://lnkd.in/eCxrkz7V Credit: Pharmafocus, July/August 2024 © Samedan Ltd
-
In the latest article of our Exploring Epilepsies series, we’re exploring the unmet need in uncontrolled #seizures and the new Rapid and Early Seizure Termination (REST) concept outlined in EpiDisorders https://lnkd.in/eR5kbeRM
-
UCBCares® is the Service Center of UCB. We are here to answer your specific questions on your UCB medication and provide you with related information and materials. UCBCares® does not replace the conversation or the medical advice of the treating doctor or is not meant to promote the medicines of UCB. #UCBCares, #Neurology, #Neurologicalcondition
-
We're excited to share the latest updates on our groundbreaking gene therapy facility in Braine-l'Alleud, Belgium. This state-of-the-art facility not only represents a significant investment in Belgium but also stands as an epitome of innovation and environmental sustainability. This project broadens our horizons, allowing us to discover and develop revolutionary cures for severe diseases and enhance our development and manufacturing capabilities. Notably, it will create over 100 new highly skilled jobs. Join us in this exciting journey as we transform the future of disease treatment. For more details, please visit our career page https://lnkd.in/garwHTg While we are incredibly proud of the strides we've made, we understand that the path to groundbreaking advancements is paved with collective effort and collaboration. Our commitment to addressing the unmet needs of patients worldwide drives us forward every single day. We are deeply grateful to our dedicated team of scientists, researchers, and partners whose hard work and passion make milestones like this possible. As we continue this journey, we remain focused on not just the outcomes but also on the people whose lives we aim to transform. Together, we aspire to build a future where innovative treatments can offer hope and tangible benefits for those affected by severe diseases. Stay tuned for more updates as we progress, and thank you for being part of our mission. For more details, check out our latest story https://lnkd.in/eTXMNPN6 #Progress #Collaboration #Hope #GeneTherapy
-
Bart is an Upstream Process Lead Engineer working on UCB’s exciting Genesis project. Find out more about a day in his life as he innovates in the field of gene therapy now, and in the future. Whether he’s taking the time for deep focus, connecting with colleagues over a freshly cooked lunch or running checks on equipment, his experience at UCB supports him and sets him up for success in his day-to-day activities and career. At UCB we have a strong human focus. We’re committed to the wellbeing of our employee community and strive to make this a workplace where people enjoy meaning and balance. https://lnkd.in/dHkyid5y #MakeYourMarkForPatients #TeamUCB #PharmaJobs
-
Hellen shares her experience navigating pregnancy and breastfeeding while living with psoriasis. Her story is reflective of many women living with #ChronicDisease and the impact on their reproductive health journey. Women deserve to have clear, evidence-based guidance on managing their condition while they are pregnant or breastfeeding to optimize their health and the health of their babies. New recommendations developed by the BRIDGE Commission, a multidisciplinary group of experts, provide practical, action-oriented solutions to overcome the information gaps that affect women living with chronic disease. Learn more and read the full report: https://lnkd.in/ekgvNzcp #WomensHealth #HealthEquity #BRIDGE4WomensHealth
-
UCB´s Service Center is called UCBCares®. Its team is here to support you by answering your questions and provide helpful information and materials around UCB medicines. UCBCares® does not replace the conversation or the medical advice of the treating doctor or is not meant to promote the medicines of UCB. #UCBCares, #Neurology, #Neurologicalcondition
-
Discover how UCB is championing a better future for women with epilepsy. From tackling info gaps to strategic collaborations, Andrea Wilkinson - Global Head of Epilepsy & Rare Syndromes Patient Engagement - takes us through how we are making a difference. https://lnkd.in/eMa8jD2f #Epilepsy #ExploringEpilepsies
-
At UCB, we're committed to elevating the standard of care by going beyond the science. Our FASTRAX program exemplifies this commitment, addressing the critical issue of delayed diagnosis of axial spondyloarthritis (axSpA). By leveraging our expertise, technology, and stakeholder collaboration, we're transforming the patient journey from the first signs of symptoms to timely diagnosis and treatment. Learn more about our innovative solutions and how we're making a real impact on the lives of those living with axSpA. #HealthcareInnovation #Rheumatology #PatientCare #FASTRAX #UCB https://lnkd.in/eje4iMtD